When Combined with Colistin, an Otherwise Ineffective Rifampicin–Linezolid Combination Becomes Active in Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii

Armengol, Eva; Asunción, Teresa; Viñas, Miguel; Sierra, Josep Maria

doi:10.3390/microorganisms8010086

Submit to this Journal Review for this Journal Edit a Special Issue

Article Menu

...

Open AccessArticle

When Combined with Colistin, an Otherwise Ineffective Rifampicin–Linezolid Combination Becomes Active in Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii

and

Laboratory of Molecular Microbiology and Antimicrobials, Department of Pathology and Experimental Therapeutics, School of Medicine. Institut d’Investigacions biomèdiques de Bellvitge (IDIBELL), University of Barcelona, 08907 L’Hospitalet, Barcelona, Spain

Author to whom correspondence should be addressed.

Microorganisms 2020, 8(1), 86; https://doi.org/10.3390/microorganisms8010086

Received: 6 December 2019 / Revised: 5 January 2020 / Accepted: 5 January 2020 / Published: 8 January 2020

(This article belongs to the Section Antimicrobial Agents and Resistance)

View Full-Text Download PDF Citation Export

Abstract

The synergistic action of colistin, with two antibiotics active in Gram-positive bacteria but unable to kill gram negatives (linezolid and rifampicin), was investigated, since triple combinations are emerging as a tool to overtake multidrug resistance. Checkerboard determinations demonstrated that, when combined with colistin, the combination of linezolid and rifampicin turns active in multidrug-resistant Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii. Thus, the presence of sublethal concentrations of colistin resulted in a strongly synergistic interaction between these two drugs. Moreover, the minimum inhibitory concentrations of linezolid–rifampicin combinations in the presence of colistin were lower than the maximal concentrations of these antimicrobials ain blood. These findings suggest the use of this triple combination as an effective treatment of multidrug-resistant (MDR) bacterial infections. View Full-Text

Keywords: antibiotic combinations; synergism; multidrug-resistant (MDR) bacteria

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Share and Cite

MDPI and ACS Style

Armengol, E.; Asunción, T.; Viñas, M.; Sierra, J.M. When Combined with Colistin, an Otherwise Ineffective Rifampicin–Linezolid Combination Becomes Active in Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii. Microorganisms 2020, 8, 86. https://doi.org/10.3390/microorganisms8010086

AMA Style

Armengol E, Asunción T, Viñas M, Sierra JM. When Combined with Colistin, an Otherwise Ineffective Rifampicin–Linezolid Combination Becomes Active in Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii. Microorganisms. 2020; 8(1):86. https://doi.org/10.3390/microorganisms8010086

Chicago/Turabian Style

Armengol, Eva, Teresa Asunción, Miguel Viñas, and Josep M. Sierra. 2020. "When Combined with Colistin, an Otherwise Ineffective Rifampicin–Linezolid Combination Becomes Active in Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii" Microorganisms 8, no. 1: 86. https://doi.org/10.3390/microorganisms8010086

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Menu

When Combined with Colistin, an Otherwise Ineffective Rifampicin–Linezolid Combination Becomes Active in Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI